The rulemaking would harmonize the DOT drug-testing program regulations on urine testing with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs. Specifically, this rulemaking would add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine (MDEA) as a confirmatory test analyte. This rulemaking would also explore burden-reducing measures, including adding clarification to certain drug-testing program provisions, removing outdated information in the regulations that is no longer needed, and removing the requirement for employers and C/TPAs to submit blind specimens.